OCGNOcugen, Inc.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product inclu…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts Ocugen (NASDAQ:OCGN) is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar | ||
 Ocugen (OCGN) Q2 2026 Earnings Call Transcript Gene therapy developer advances three Phase III programs toward 2028 regulatory filings. | ||
 Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028. | ||
 Ocugen Q2 Earnings Call Highlights Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program. Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri sa | ||
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ... Ocugen Inc (OCGN) advances its gene therapy pipeline with key regulatory milestones and strategic partnerships, despite a wider net loss and delayed BLA submission. | ||
 Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates Illumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||